Oruka reports positive Week 16 psoriasis data and plans Phase 3 development
+1 new source since this summary was written
Oruka Therapeutics reported October 26 Week 16 results from the Phase 2b EVERLAST-B study of ORKA-001 in adults with moderate-to-severe plaque psoriasis. In the 600 mg group, 61% of patients reached PASI 100 and 86% reached PASI 90. Oruka plans to discuss Phase 3 development with regulators and targets starting Phase 3 trials in the first half of 2027.
Why it matters
The results provide clinical support for advancing ORKA-001 toward Phase 3, although regulatory discussions and longer-term durability data remain ahead. Guggenheim reiterated a Buy rating and a $200 price target, citing the trial results, according to the material.
Key facts
- 1EVERLAST-B was a randomized, double-blind, placebo-controlled Phase 2b study involving 187 patients across 36 sites. ibtimes.com.au
- 2At Week 16, 61% of patients receiving 600 mg achieved PASI 100 and 86% achieved PASI 90. ibtimes.com.au
- 3The company reported no serious or severe side effects in the 600 mg group through Week 16. ibtimes.com.au
- 4Oruka expects Week 52 data from the separate EVERLAST-A study in December. ibtimes.com.au
- 5The company plans to advance the 600-milligram dose into Phase III, with initiation targeted for the first half of 2027. finance.yahoo.com
Open questions
- Oruka has not finalized the Phase 3 trial design or active comparator choice.
- The company's proposed annual maintenance schedule still depends on later durability data and further trials.
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.